|
| Human CLEC12A/MICL/CLL-1 Protein (LTP10721) |
|
| LTP10721 |
|
| 100ug |
|
|
$519 In stock |
| CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. |
| Recombinant Human CLEC12A/MICL/CLL-1 Protein is expressed from Expi293 with hFc tag at the N-terminal. It contains His65-Ala265. |
|
| CLEC12A/MICL/CLL-1 |
|
| Human |
|
| Q5QGZ9-2 |
|
| His65-Ala265 |
|
| The protein has a predicted MW of 50.9 kDa. Due to glycosylation, the protein migrates to 68-73 kDa based on the Tris-Bis PAGE result. |
|
| Immobilized Human CLEC12A, hFc Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC12A Antibody, hFc Tag with the EC50 of 20.2ng/ml determined by ELISA. See testing image for detail. |
|
| N-hFc |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
